colistin sulphate
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
5023
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
December 12, 2025
Celastrol Mitigates Colistin-Induced Renal Toxicity in Rats via Modulating Nrf-2/HO-1 and NF-κB Signaling Pathways.
(PubMed, J Biochem Mol Toxicol)
- "In contrast, pretreatment with CELA significantly reduced the histopathological changes, oxidative stress, inflammation, and apoptosis. Therefore, CELA showed significant renal protection against CST-induced kidney injury."
IO biomarker • Journal • Preclinical • Fibrosis • Infectious Disease • Inflammation • Ophthalmology • Renal Disease • BCL2 • CASP3 • CST3 • NFKB1 • TNFA
December 12, 2025
Emergence and genomic characterization of mcr-8.2-positive Klebsiella pneumoniae from layer chickens in Xinjiang, China.
(PubMed, Poult Sci)
- "To our knowledge, this is the first report of mcr-8.2-positive K. pneumoniae in layer chickens in Xinjiang, China. These findings highlight the contribution by mobile genetic elements (MGEs) to cross-species dissemination of colistin resistance and emphasize the necessity of a One Health strategy for monitoring and controlling such pathogens and AMR."
Journal • Infectious Disease • Pneumonia
December 12, 2025
Comparative analysis of colistin and polymyxin B minimal inhibitory concentrations in Enterobacterales, Acinetobacter baumannii, and Pseudomonas aeruginosa.
(PubMed, J Infect Public Health)
- "Colistin and polymyxin B showed comparable in vitro activity and high MIC correlation. Colistin reliably predicted polymyxin B susceptibility, but caution is needed when inferring colistin susceptibility from polymyxin B results."
Journal • Infectious Disease
December 12, 2025
CRISPRSpacerType: Automated CRISPR typing of Cronobacter spp. for contamination tracing and evolutionary analysis via spacer profiles.
(PubMed, Int J Food Microbiol)
- "Most importantly, significant associations were found linking specific CT types to both predominant colistin antibiotic resistance gene mcr-9.1 carriage and pathogenicity...This advancement significantly strengthens outbreak prevention and surveillance efforts against this pathogen. Our tool is available from GitHub at https://github.com/zwxyo/CRISPRSpacerType."
Journal • Infectious Disease
December 12, 2025
Various Bacillus and Paenibacillus Spp. Isolated From Soil Produce Compounds With Potent Antimicrobial Activity Against Clinically Relevant Pathogens.
(PubMed, Microbiologyopen)
- "While many of these clusters were not associated with known antimicrobial compounds, several of them displayed high similarity to known compounds such as polymyxin B, paenilan, colistin, and paenibacterin. These findings reinforce numerous previous studies highlighting the potential of soil-derived Bacillus and Paenibacillus species as valuable sources of novel antimicrobials to address the global antibiotic resistance crisis."
Journal • Infectious Disease • Metabolic Dysfunction-Associated Steatohepatitis
December 11, 2025
Colistin-resistant Pseudomonas aeruginosa: an emerging threat in surgical and cancer patients.
(PubMed, Ann Med Surg (Lond))
- "Novel therapeutic strategies, including combination therapy and phage-based approaches, should be explored to mitigate the impact of CRPA in vulnerable surgical and cancer patient populations. Addressing this emerging threat is essential to improve clinical outcomes and reduce healthcare burdens."
Journal • Infectious Disease • Oncology
December 11, 2025
Nitroxoline as an antimicrobial synergist reverses colistin resistance in multidrug-resistant Escherichia coli.
(PubMed, iScience)
- "Furthermore, in both the Galleria mellonella and mouse peritonitis infection models, NTX improved the therapeutic effect of colistin against E. coli infections. In conclusion, NTX is identified as a promising colistin adjuvant for the treatment of colistin-resistant bacterial infections."
Journal • Infectious Disease
December 11, 2025
Power of Combined Intravenous and Intraventricular Colistin Against Multidrug-Resistant Bacteria in Healthcare-Associated Ventriculitis and Meningitis.
(PubMed, Cureus)
- "While clinical outcomes may be limited by underlying neurological severity, adjunct IVT therapy ensures effective CSF antibiotic concentrations and may improve infection control. Further research is needed to optimize dosing and establish standardized treatment protocols."
Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Infectious Disease • Pneumonia • Ventriculomegaly
December 11, 2025
Colistin use in neonates with multidrug-resistant Gram-negative infections: challenges in antimicrobial stewardship.
(PubMed, Ann Med Surg (Lond))
- "Evidence reveals that a significant proportion of neonatal colistin use is empiric rather than culture-driven, underscoring the gap between guidelines and clinical practice. Strengthening stewardship frameworks, integrating therapeutic drug monitoring, and adopting real-time resistance surveillance are essential to safeguard colistin efficacy and mitigate resistance spread among vulnerable neonatal populations."
Journal • Critical care • Infectious Disease • Septic Shock
December 05, 2025
Activity of aztreonam-avibactam, cefiderocol, and cefepime-taniborbactam against a global collection of genetically characterized metallo-β-lactamase-producing Enterobacterales.
(PubMed, Antimicrob Agents Chemother)
- "Tigecycline and colistin inhibited 94.1% and 76.6% of the isolates (FDA and EUCAST breakpoints, respectively). MBL-producing organisms are still considered an unmet medical need. Aztreonam-avibactam was active against this large collection of MBL-producing isolates that had elevated MIC values for many comparator agents."
Journal
December 11, 2025
Convergence of plasmid-driven virulence and antibiotic resistance in Escherichia coli.
(PubMed, Nat Commun)
- "We further describe ColVLP co-integrates that have acquired extensive resistance profiles, including against last line colistin, through recombination with co-resident plasmids. Using pMS7163A, a ColVLP from a virulent ExPEC strain, we also demonstrate that the ColVLP-encoded outer membrane protease virulence factor OmpTp works co-operatively with its chromosomal homolog to enhance ExPEC resistance against human cathelicidin (LL-37), an antimicrobial peptide expressed in the urinary tract. Together, our work characterises ColVLPs as high-risk mobile genetic elements that amplify the convergence of resistance and virulence in ExPEC."
Journal • Infectious Disease
December 11, 2025
Effects of colistin stress on growth, antioxidant system and metabolite pattern of lettuce.
(PubMed, BMC Plant Biol)
- "This study developed a rapid LC-MS/MS method for the detection of colistin in lettuce. Colistin was found to upregulate 11 (R)-HETE and decrease 5,6-DHET and prostaglandin G2 by inhibiting the phospholipid-arachidonic acid metabolic pathway, thereby inducing oxidative stress and compromising organelle integrity in lettuce. Analysis of real samples indicated that the potential health risk from colistin exposure through dietary intake is low. Nevertheless, further research is required to evaluate the potential risks related to antibiotic resistance and the synergistic toxicity of colistin in combination with other contaminants."
Journal • CAT
December 10, 2025
Bacterıal pathogens ın ventılator-assocıated pneumonıa; molecular assessment of resıstance profıles.
(PubMed, Folia Microbiol (Praha))
- "baumannii strains exhibited 100% resistance to ciprofloxacin and carbapenems, and 70.83% to colistin...pneumoniae strains demonstrated 94.73% resistance to carbapenems and 100% to piperacillin-tazobactam and colistin...This study provides a comprehensive molecular characterisation of VAP pathogens based on an extensive dataset. The results underscore the need for stricter infection control, restrained use of broad-spectrum antibiotics, and ongoing surveillance of resistance mechanisms."
Journal • Critical care • Infectious Disease • Pneumonia • Respiratory Diseases
December 10, 2025
Carbapenem-resistant Klebsiella pneumoniae from clinical infections: a multifactorial analysis of resistance, virulence, and biofilm potential.
(PubMed, Front Cell Infect Microbiol)
- "MIC testing showed high resistance to meropenem (71%), colistin (61%), and tigecycline (43%). These findings highlight the convergence of antimicrobial resistance, virulence factors, and biofilm-forming capacity in K. pneumoniae. The coexistence of these traits promotes persistence, increases pathogenic potential, and complicates therapeutic interventions, emphasizing the urgent need for strengthened infection control and alternative treatment strategies."
Journal • Infectious Disease • Pneumonia
December 10, 2025
Evaluation of Synergistic Effect of Colistin with Levofloxacin and Meropenem against Multidrug-resistant Acinetobacter baumannii.
(PubMed, J Res Pharm Pract)
- "However, only 40% of isolates demonstrated partial synergism with no instances of antagonistic behavior when colistin and levofloxacin were administered together. Levofloxacin and meropenem exhibit respectable synergistic effects when combined with colistin; as a result, these combinations may be clinically assessed for MDR-AB infections."
Journal • Infectious Disease
December 09, 2025
Epidemiological profile of causative agents in nosocomial pneumonia: a four-year multicenter surveillance study from Georgia (2020-2023).
(PubMed, Infection)
- "This four-year study shows high and increasing antimicrobial resistance among NP pathogens in Georgia, especially in ICU settings. The rise in ESBL, carbapenemase, and colistin resistance highlights the need to strengthen antimicrobial stewardship, infection prevention, and genomic surveillance to control the spread of high-risk strains and improve patient outcomes in resource-limited settings."
Journal • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases
December 09, 2025
Deciphering the emergence of mutations in Pseudomonas aeruginosa after ceftolozane/tazobactam treatment and evaluating therapeutic alternatives.
(PubMed, BMC Microbiol)
- "Ceftolozane/tazobactam resistance development was associated mainly with chromosomal mutations in the ampC gene but also with mutations in its regulatory genes. Knowledge about these mutations and gene polymorphisms is essential for interpreting resistance phenotypes from genomic data."
Journal
December 08, 2025
Quantification of Polymyxin E in Plasma and Epithelial Lining Fluid: Validation and Clinical Application.
(PubMed, J Pharm Biomed Anal)
- "In this study, we developed and validated a sensitive LC-MS/MS method for quantifying PME in plasma and epithelial lining fluid (ELF) from patients receiving colistin sulfate therapy...Overall, this validated method is suitable for routine TDM of PME. The findings support future studies to evaluate plasma trough levels and ELF concentrations in guiding individualized therapy for critically ill patients."
Journal • Acute Kidney Injury • Infectious Disease • Nephrology • Renal Disease
December 07, 2025
Beyond the matrix: rethinking antibiotic tolerance in CF biofilms using 3D models.
(PubMed, NPJ Biofilms Microbiomes)
- "Acetylation further enhances tolerance, particularly to tobramycin, ciprofloxacin, and colistin. This demonstrates that direct interaction with alginate or DNA does not explain the slow diffusion of antibiotics in mucoid P. aeruginosa biofilms. Our findings challenge the view that diffusion limitation or antibiotics binding by biofilm exopolysaccharides dominate biofilm resilience and highlight the need to target matrix-induced bacterial adaptation in the development of antibiofilm therapies."
Journal • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Pulmonary Disease • Respiratory Diseases
December 06, 2025
Reducing incorrect antibiotic dosing and enhancing prescriber adherence through a real-time, patient-specific clinical decision support system: A post-implementation evaluation.
(PubMed, Br J Clin Pharmacol)
- "By integrating real-time, patient-specific parameters into the prescribing process and offering guideline-aligned recommendations, this CDSS significantly improved prescriber adherence and reduced incorrect antibiotic dosing. The system shows strong potential to improve medication safety and support antimicrobial stewardship."
Journal • Genetic Disorders • Obesity • Renal Disease
December 06, 2025
Colistin-Induced Bartter-Like Syndrome With Torsades de Pointes: A Reversible Cause of Life-Threatening Arrhythmia.
(PubMed, JACC Case Rep)
- "Colistin may rarely cause Bartter-like syndrome with electrolyte disturbances (hypokalemia, hypocalcemia, hypomagnesemia, and metabolic alkalosis) leading to TdP. In patients with drug-refractory QT prolongation, medication review is crucial to rule out rare secondary causes."
Journal • Cardiovascular • Endocrine Disorders • Infectious Disease • Metabolic Disorders • Nephrology • Ventricular Tachycardia
December 05, 2025
Global epidemiological and genetic characteristics of carbapenem-resistant Escherichia coli carrying blaIMP.
(PubMed, Microbiol Spectr)
- "The nine isolates were multidrug-resistant but susceptible to colistin, tigecycline, and amikacin. Additionally, the study elucidated the global epidemiological status, transmission features, and potential threats of blaIMP-positive CRECs through a large-scale analysis of publicly available genomic data. These findings not only facilitate a better understanding of the genetic dynamics and transmission pathways of blaIMP but also help develop effective regulatory measures and antibiotic stewardship programs to alleviate the increasingly severe burden of antimicrobial resistance."
Journal
December 05, 2025
Terrestrial plastisphere as a reservoir of high-risk mcr-1-positive Escherichia coli ST744 in a farmhouse.
(PubMed, J Glob Antimicrob Resist)
- No abstract available
Journal
December 05, 2025
PERi-operative selective decontamination of the digestive tract to prevent severe infectious complications after Esophageal Resection: study protocol of the PERSuaDER-trial, a multicenter randomized controlled trial in patients with primary resectable esophageal carcinoma.
(PubMed, Trials)
- P3 | "It is hypothesized that the addition of SDD to the standard peri-operative care in esophageal cancer surgery will result in a reduction in the incidence of postoperative pneumonia. Furthermore, the trial will evaluate the impact of SDD on postoperative (infectious) complications and quality of life, and its cost-effectiveness."
Journal • Esophageal Cancer • Gastrointestinal Disorder • Infectious Disease • Oncology • Pneumonia • Respiratory Diseases
December 04, 2025
From structured surveys to outbreak investigations: advancing genomic surveillance of carbapenem-resistant Enterobacterales within the European Antimicrobial Resistance Genes Surveillance Network.
(PubMed, Front Public Health)
- "The European Antimicrobial Resistance Genes Surveillance Network (EURGen-Net) was established in 2017 to support the European survey of carbapenem- and/or colistin-resistant Enterobacterales in 37 countries. In parallel to large-scale international structured surveys with a central whole genome sequencing (WGS), EURGen-Net rapidly developed an approach for faster and more flexible investigations of cross-border outbreaks and emerging antimicrobial resistance of international concern in Europe, based on voluntary sharing of national WGS and epidemiological data for joint analysis. Here, we describe the approach and methodology, practical experience with implementation, benefits and challenges of the current model for genomic surveillance of carbapenem-resistant Enterobacterales at the European level."
Journal
1 to 25
Of
5023
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201